Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Afatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 10/20 | 1.00 |
| ▸ | ERBB4 known ✓ | Q15303 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | MET | P08581 | 2/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 2/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 1.00 |
| ▸ | IRAK1 | P51617 | 2/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 2/20 | 1.00 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 1.00 |
| ▸ | EPHA6 | Q9UF33 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Afatinib SCHEMBL28567422 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL232772 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL29733662 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL2865630 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL231072 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL185621 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL2865634 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL185786 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL231073 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL28409673 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112955137-A | Combination therapy | 米拉蒂治疗股份有限公司 | 2021-06-11 | — | — | CN | claimed |
| CN-111297865-A | Use of heterocyclic compound-containing composition for preparing medicine for treating lung cancer | 黄泳华 | 2020-06-19 | — | — | CN | claimed |
| US-8735409-B2 | Quinazoline derivatives | ZHANG QIANG (US) | 2014-05-27 | — | — | US | claimed |
| US-20130035350-A1 | Novel Quinazoline Derivatives | ZHANG QIANG (US) | 2013-02-07 | — | — | US | claimed |
| WO-2011084796-A2 | NOVEL QUINAZOLINE DERIVATIVES | ZHANG QIANG | 2011-07-14 | — | — | WO | claimed |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2025-10-30 | — | — | US | disclosed |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2024-10-31 | — | — | US | disclosed |
| WO-2023187037-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR (EGFR) TYROSINE KINASE INHIBITORS IN COMBINATION WITH AN AKT INHIBITOR FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2023-10-05 | — | — | WO | disclosed |
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | ONCOSELECT THERAPEUTICS, LLC (US) | 2023-09-28 | — | — | US | disclosed |
| EP-4223770-A2 | NOVEL FUSION MOLECULES AND USES THEREOF | Foundation Medicine, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| EP-2914622-B1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUND MEDICINE INC (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2011084796-A2 | NOVEL QUINAZOLINE DERIVATIVES | ZHANG QIANG | 2011-07-14 | — | — | WO | disclosed |
| US-7960546-B2 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-14 | — | — | US | disclosed |
| US-7960546-B2 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-06-14 | — | — | US | disclosed |
| US-20090306378-A1 | PROCESS FOR PREPARING AMINOCROTONYLAMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| US-20090306378-A1 | PROCESS FOR PREPARING AMINOCROTONYLAMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-12-10 | — | — | US | disclosed |
| WO-2007085638-A1 | PROCESS FOR PREPARING AMINOCROTONYLAMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-08-02 | — | — | WO | disclosed |
| US-20070027170-A1 | Process for preparing amino crotonyl compounds | SOYKA RAINER | 2007-02-01 | — | — | US | disclosed |
| US-20070027170-A1 | Process for preparing amino crotonyl compounds | SOYKA RAINER | 2007-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070027170-A1 | Process for preparing amino crotonyl compounds | CROCC, CMA1, IL4I1 | EGFR 3654/4885ERBB2 3381/4885ERBB4 2122/4885 |
| US-20130035350-A1 | Novel Quinazoline Derivatives | ERBB2, ERBB3, EGFR | EGFR 3/4885ERBB2 1/4885ERBB4 4/4885 |
| US-20230302144-A1 | Porphyrin Compounds and Compositions Useful for Treating Cancer | KIT, HCCS, PPIF | EGFR 1166/4885ERBB2 1246/4885ERBB4 2954/4885 |
| US-20240360199-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | EGFR 2414/4885ERBB2 1580/4885ERBB4 1681/4885 |
| US-20090306378-A1 | PROCESS FOR PREPARING AMINOCROTONYLAMINO-SUBSTITUTED QUINAZOLINE DERIVATIVES | EGFR, CNKSR1, ERBB2 | EGFR 1/4885ERBB2 3/4885ERBB4 5/4885 |
| US-20250333479-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | EGFR 2414/4885ERBB2 1580/4885ERBB4 1681/4885 |
| US-20250333480-A1 | FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | EGFR 2095/4885ERBB2 1560/4885ERBB4 1596/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.